Organization
Revimmune
3 clinical trials
Clinical trial
Recombinant Human InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic PAtients With COVID-19 Infection - "ILIAD 7 Trial" Brazil CohortStatus: Terminated, Estimated PCD: 2021-12-31
Clinical trial
Recombinant Interleukin-7 (CYT107) to Treat Patients With Refractory Nontuberculous Mycobacterial Lung Disease. Two Doses Phase II, Single Center, Open-label TrialStatus: Terminated, Estimated PCD: 2023-12-31
Clinical trial
A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection. US Oncology CohortStatus: Terminated, Estimated PCD: 2022-06-30